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BACKGROUND: This analysis was initiated to define the predictive value of the area under the curve of high-dose methotrexate
(AUCHD-MTX) in patients with primary central nervous system lymphoma (PCNSL).
PATIENTS AND METHODS: We included 55 patients with PCNSL and available pharmacokinetic (PK) data from the International
Extranodal Lymphoma Study Group (IELSG) no. 20 trial, randomised to HD-MTX (n¼30) or HD-MTX and high-dose cytarabine
(HD-AraC) (n¼25). Individual AUCHD-MTX from population PK analysis was tested on drug toxicity and clinical outcome using
multivariate logistic regression analysis and Cox hazards modelling.
RESULTS: AUCHD-MTX, the IELSG score and treatment group were significant predictors for treatment response (complete or partial)
in the adjusted model. The AUCHD-MTX did not predict toxicity, with the exception of liver toxicity and neutropaenia. A high
AUCHD-MTX was associated with better event-free survival (EFS) (P¼0.01) and overall survival (OAS) (P¼0.02). Both the AUCHD-MTX
and the IELSG score were significant predictors of EFS and OAS in the adjusted model, with a hazard ratio of 0.82 and 0.73,
respectively, per 100mmoll
 1h
 1 increase in AUCHD-MTX.
CONCLUSIONS: Individualised dosing of HD-MTX might have the potential to improve clinical outcome in patients with PCNSL, even
when administered concurrently with HD-AraC. In the future, this could be carried out by using first-cycle PK modelling with
determination of potential dose adaptations for later cycles using Bayesian analysis.
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Primary central nervous system lymphomas (PCNSLs) represent
4–6% of extranodal non-Hodgkin’s lymphomas, but their
incidence in the general population is increasing (Ferreri et al,
2003a). High-dose methotrexate (HD-MTX) is a cornerstone of
PCNSL treatment (Reni et al, 1997; Ferreri et al, 2002). Only
recently, the International Extranodal Lymphoma Study Group
(IELSG) concluded the first randomised study in immunocompe-
tent patients with PCNSL (IELSG no. 20). A significant increase in
complete remission rate and event-free survival (EFS) was found
when adding high-dose cytarabine (HD-AraC) to HD-MTX
(Ferreri et al, 2009). Accordingly, combined HD-MTX/HD-AraC
should be seen as the new standard upfront treatment in PCNSL, as
it is supported by the best level of evidence available in this disease
(Ferreri et al, 2009). Treatment with HD-MTX is hampered by
a highly variable pharmacokinetic (PK) behaviour, in part related
to renal elimination and the potential for drug interactions (Evans
and Christensen, 1985; Thyss et al, 1986; Ferrazzini et al, 1990;
Reid et al, 1993; Ronchera et al, 1993; Takeda et al, 2002; Joerger
et al, 2006). However, achieving a minimum area under the curve
(AUC) of HD-MTX (AUCHD-MTX) might be important for clinical
outcome in patients with PCNSL (Ferreri et al, 2004). In this study,
we report a PK–pharmacodynamic (PKPD) analysis of HD-MTX
in patients enrolled into the IELSG no. 20 trial, to define the
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spredictive value of AUCHD-MTX and to identify clinical and thera-
peutic variables that could be manipulated to improve MTX
efficacy in patients with PCNSL.
MATERIALS AND METHODS
Patient population and treatment
We included 79 immunocompetent patients with PCNSL, rando-
mised to receive either HD-MTX alone (n¼40) or HD-MTX
with sequential HD-AraC (n¼39) from the IELSG no. 20 trial
(Ferreri et al, 2009). High-dose MTX was administered at 3.5gm
 2
(0.5gm
 2 in 15min, followed by 3gm
 2 as a 3h infusion) on
day 1 in both arms, and HD-AraC was administered at 2gm
 2 as a
1h infusion every 12h on days 2 and 3 in the combined treatment
arm. Radiotherapy was given after chemotherapy in 36 patients,
and at progression in 18 patients. Study design and inclusion
criteria have been published previously (Ferreri et al, 2009). The
determination of MTX serum levels was performed before and
immediately after the end of drug infusion, and repeated every
24h until the MTX serum concentration fell under the threshold
concentration of 0.05mmoll
 1. The concentration data of MTX
– collected at 0, 24, 48, 72 and 96h from drug infusion – during the
first course of chemotherapy were considered for PK analysis.
Leucovorin rescue started 24h after the start of HD-MTX infusion,
administered at a dose of 15mgm
 2 intravenous push every 6h
for 12 times or more until MTX serum levels were undetectable.
After 48h from MTX infusion, leucovorin rescue was modified
according to MTX serum levels.
Population PK analysis
Population PK analysis was performed using the nonlinear
mixed-effects modelling program (NONMEM) version VI (double
precision, level 1.1) (Beal and Sheiner, 1998). First, a basic PK
model was developed for MTX concentration–time data. Model
selection was based on the minimum value of objective function,
the precision of parameter estimates and the fit of the model to the
data as approached by graphical plots. Inter-individual variability
was estimated using a proportional error model. Second, the
following covariates were tested for their relationship with CLMTX:
patient gender, age, body-surface area (BSA), creatinine clearance
(CLCREA according to the Cockroft–Gault formula, assessed before
the start of MTX infusion and capped at 140mlmin
 1), as well as
co-medication with anticonvulsant drugs and steroids. Forward
selection and backward elimination were used for covariate testing,
with a significance level of Po0.01.
Toxicity and response assessment
Adverse events were separately assessed for each chemotherapy
course and graded according to the NCI-NCIC CTC version 3.0
(Trotti et al, 2003). The worst toxicity per organ and per patient
was considered for analysis. Treatment response was assessed on
contrast-enhanced brain MRI performed within 7 days before
chemotherapy and repeated after the second and fourth treatment
cycle and after WBRT. Response definition was based on changes
in tumour size of enhanced lesions on T1-weighted MRI, and
following the NCI standardised response criteria (Cheson et al,
1999). In cases with concomitant positive CSF, cytology exami-
nation was performed after the second and fourth treatment
cycle and after treatment completion. A reduction of 450% of
cell number was considered PR, whereas a lower reduction was
considered SD. The maximum response recorded from treatment
start was considered for activity analyses. Follow-up examinations
were conducted as reported previously (Ferreri et al, 2003a).
Statistical analysis
Individual AUCHD-MTX was compared between treatment groups,
patient gender and treatment response using Student’s t-test.
Patients were categorised into those having no response to
chemotherapy (SD, PD) and responders (CR or PR). Analysis
of variance (ANOVA) was used to compare individual AUCHD-MTX
with treatment-associated toxicity. To assess any potential
relationship between AUCHD-MTX and clinical outcome, the former
was categorised into tertiles, with the higher tertile corresponding
to an AUC 4980mmoll
 1h and the lower tertile corresponding to
an AUC o830mmoll
 1h. Both EFS and overall survival (OAS)
were calculated per AUCHD-MTX category using survival analysis
and log-rank test, respectively. The following potential predictors
for chemotherapy response were studied using multivariate logistic
regression analysis: AUCHD-MTX (tertiles), gender, categorical
IELSG prognostic score (Ferreri et al, 2003b) (0–1,
2–3, 4–5 points) and treatment group. The following potential
predictors for clinical outcome (EFS, OAS) were studied using
multivariate Cox hazards modelling: gender, IELSG score,
treatment group and AUCHD-MTX. Both EFS and OAS curves were
calculated using the Kaplan–Meier method, and the log-rank
test was used to detect potential differences per AUCHD-MTX
category. A previously described threshold of AUCHD-MTX
X1100mmoll
 1h (Ferreri et al, 2004) was additionally analysed
on chemotherapy response and clinical outcome. All tests of
significance were two-sided; Po0.05 was considered significant.
All statistical analyses were performed using STATA 10.1 software
(STATA Corp, College Station, TX, USA).
RESULTS
Patient population and data set
Patient characteristics have been described previously (Ferreri
et al, 2009). Out of the 79 patients, 55 had available PK data of
HD-MTX and were included into this analysis with the following
characteristics: median age 56 years, 32 female (58%) and 23 male
(42%); 30 patients were randomised to receive HD-MTX and
25 patients to combined HD-MTX/HD-AraC, with a median
IELSG-score of 2. Patient characteristics of the PKPD subgroup
and of the total population were not significantly different. After
chemotherapy, 7 HD-MTX and 18 HD-MTX/HD-AraC patients
achieved a CR (18 vs 46%; P¼0.006); 9 MTX and 9 MTX/AraC
patients achieved a PR, for an ORR of 40 and 69%, respectively
(P¼0.009). At a median follow-up of 30 months, 31 MTX and
23 MTX/AraC patients experienced failure (PD, relapse, death),
with a 3-year EFS of 21 and 38%, respectively (P¼0.01). In all,
12 MTX and 20 MTX/AraC patients are alive, with a 3-year OAS
of 32 and 46%, respectively (P¼0.07).
Population PK model
The MTX concentration–time data were best described by a linear
two-compartment model with first-order elimination from the
central compartment. The MTX clearance was 14.9lh
 1 (relative
s.e. 9.95), with an inter-individual variability of 22.3% and a resi-
dual variability of 31.8%. Volume distribution was 71.9l (±51.5),
with an inter-individual variability of 30.1%. Inter-compartmental
clearance was 11.2lh
 1 (±5.2), with an inter-individual variabi-
lity of 35%. Two patients had a CLHD-MTX 420lh
 1, six patients
o7lh
 1. Median AUCHD-MTX was 931mmol*l
 1h (range 486–
1710mmol*l
 1h). The AUCHD-MTX was o750mmoll
 1h in 11 out
of 55 cases with available PK data (20%), and 41100mmoll
 1hi n
12 cases (22%). Creatinine clearance was the only significant
covariate on CLHD-MTX, resulting in Equation 1 to describe
CLHD-MTX as a function of CLCREA (95mlmin
 1 is the median
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sCLCREA as found in the study group):
CLHD MTX¼ 14:9  ð CLCREA=95Þ
0:368 ð1Þ
The inclusion of patient age, BSA or concurrent administration
of HD-AraC did not improve the model fit. The goodness-of-fit
plots supported a good data fit of the final model (Figure 1).
Statistical analysis
The AUCHD-MTX tertiles are outlined across chemotherapy res-
ponse and clinical outcome in Table 1. The AUCHD-MTX was not
significantly different between treatment groups (902mmol*l
 1hi n
the HD-MTX group, 965mmol*l
 1h in the HD-MTX/HD-AraC
group, P¼0.16). The AUCHD-MTX was significantly higher in the 29
responding patients compared with the 26 cases without chemo-
therapy response (1075 vs 867mmol*l
 1h, P¼0.0001). Predictors
of a favourable treatment response are outlined in Table 2. Patients
with AUCHD-MTX 41100mmol*l
 1h had an odds ratio of 3.5 for
having a favourable treatment response (P¼0.03). There was
no significant relationship between AUCHD-MTX and toxicity, with
the exception of liver dysfunction (AUCHD-MTX 1047mmol*l
 1hi n
patients with any treatment-associated liver dysfunction vs
932mmol*l
 1h in those without liver dysfunction, P¼0.02) and
neutropaenia (AUCHD-MTX 1036mmol*l
 1h in patients with grade 3
or 4 neutropaenia vs 914mmol*l
 1h in those with no or grade 1 or
2 neutropaenia, P¼0.007). Patients with the highest AUCHD-MTX
exhibited a significantly better EFS and OAS as compared with
patients in the lower two tertiles of AUCHD-MTX (Table 2 and
Figure 2). The AUCHD-MTX 41100mmol*l
 1h was associated
with a better EFS and OAS by the log-rank test (P¼0.023 and
P¼0.056, respectively). Both the AUCHD-MTX and the IELSG
score were significant predictors of EFS and OAS using multi-
variate Cox regression analysis (Table 3). When AUCHD-MTX
41100mmol*l
 1h was introduced into Cox regression analysis as
a binary covariate, statistical significance was retained (HR¼0.51,
P¼0.033 for EFS, HR¼0.50, P¼0.044 for OAS). No association
was found between the volume of distribution, inter-compart-
mental clearance and any of the clinical end points.
DISCUSSION
This PKPD analysis of HD-MTX in patients from the IELSG no. 20
trial is of special value, as this is the first prospective, randomised
trial in PCNSL with completed accrual (Ferreri et al, 2003a). This
study shows that AUCHD-MTX is the most important and
independent predictor of clinical outcome in this group of
patients. This is an important issue considering the fact that the
HD-MTX/HD-AraC combination is the new standard therapeutic
approach to patients with PCNSL (Ferreri et al, 2009). Interest-
ingly, this study showed that nearly 75% of patients did not
achieve an AUCHD-MTX 41100mmol*l
 1h, which has been
previously reported as an independent predictor for improved
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Figure 1 Goodness-of-fit plots of the final population pharmacokinetic model (all data log-transformed, drug concentration as mmoll
 1). Observed MTX
concentrations vs model predictions (A) and vs individual Bayesian predictions (B).
Table 1 Comparison between AUCHD-MTX tertiles, chemotherapy response and clinical outcome
AUClow (o830lmoll
 1h) AUCmid (830–980lmoll
 1h) AUChigh (4980lmoll
 1h)
Covariate Pts (%) OR (95% CI) Pts (%) OR (95% CI) Pts (%) OR (95% CI) P-value
ORR
SD/PD 14 (54) Ref 10 (39) Ref 2 (7) Ref
CR/PR 5 (17) 0.18 (0.05–0.61) 8 (28) 0.61 (0.19–1.89) 16 (55) 14.7 (2.93–74.4) o0.001
a
Pts (%) % Pts (%) % Pts (%) %
Outcome
3-Year EFS 19 (34) 21.1 18 (33) 20.8 18 (33) 32.1 0.04
b
3-Year OAS 19 (34) 30.7 18 (33) 30.5 18 (33) 46.0 0.06
b
Abbreviations: AUCHD-MTX¼area under the curve of high-dose methotrexate; Pt¼patient; OR¼odds ratio; CI¼confidence interval; ORR¼objective response rate;
SD¼stable disease; PD¼progressive disease; CR¼complete response; PR¼partial response; Ref¼reference; EFS¼event-free survival; OAS¼overall survival.
aAnalysis of variance.
blog-rank test.
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sclinical outcome (Ferreri et al, 2004). The present results cannot be
interpreted as a lack of benefit from combined HD-MTX/HD-AraC
treatment, as not all patients had available PK data for HD-MTX,
and combined HD-MTX/HD-AraC treatment was still a significant
predictor for clinical outcome when AUCHD-MTX was dropped
from the Cox model. It still indicates that inter-individual
disparities in HD-MTX pharmacology have an important role in
clinical outcome, and that optimising individual AUCHD-MTX is an
important strategy for improving clinical outcome in PCNSL.
Thus, the encouraging results of the IELSG no. 20 trial (Ferreri
et al, 2003a) might be further improved by individualised
MTX administration aimed to achieve a target AUCHD-MTX of
1000mmol*l
 1h. This statement is also endorsed by the fact that
there was no relevant impact of AUCHD-MTX on drug toxicity. The
strengths of this study include a homogeneous patient population,
the availability of detailed response, outcome and toxicity data in
all patients, first-course PK data of MTX in most patients, as well
as population PKPD analysis of HD-MTX time–concentration
data. The main limitations of this study are that drug interactions
between HD-MTX and HD-AraC could only indirectly be studied
because no PK data of HD-AraC were available, and PK data of
Table 2 Predictors for chemotherapy response (complete and partial
remission) using multivariate regression modeling
Covariate OR 95% CI P-value
Patient gender
Male Ref
Female 0.48 0.08–2.92 0.42
IELSG risk score
0–1 Ref
2–3 0.05 0.005–0.44 0.007
4–5 0.03 0.002–0.48 0.01
Treatment group
HD-MTX Ref
HD-MTX/HD-AraC 9.33 1.33–65.53 0.02
AUCHD-MTX (tertiles, mmoll
 1h
 1)
o830 Ref
830–980 5.21 0.73–37.3 0.10
4980 121.9 7.80–190.1 0.001
Abbreviations: OR¼odds ratio; CI¼confidence interval; IELSG¼International
Extranodal Lymphoma Study Group; HD-MTX¼high-dose methotrexate; HD-
AraC¼high-dose cytarabine; AUC¼area under the curve; Ref¼reference.
Log-rank P=0.01 Log-rank P=0.02
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Figure 2 Kaplan–Meier plots for event-free survival (A) and overall survival (B) grouped according to the highest AUCHD-MTX tertile (4980mmol*l
 1h)
and the lower two tertiles of AUCHD-MTX (o980mmol*l
 1h).
Table 3 Predictors for event-free and overall survival using multivariate
Cox regression analysis
Covariate HR 95% CI P-value
Event-free survival
Patient gender
Female Ref
Male 1.12 0.52–2.40 0.77
IELSG score
0–1vs 2–3vs 4–5 points 1.71 1.04–2.81 0.03
Treatment group
HD-MTX Ref
HD-MTX/AraC 0.65 0.34–1.25 0.19
AUCHD-MTX
Per 100mmoll
 1h increase 0.82 0.69–0.98 0.03
Overall survival
Patient gender
Female Ref
Male 1.77 0.76–4.10 0.19
IELSG score
0–1vs 2–3vs 4–5 points 1.82 1.00–3.31 0.05
Treatment group
HD-MTX Ref
HD-MTX/AraC 0.80 0.39–1.65 0.54
AUCHD-MTX
Per 100mmoll
 1h increase 0.73 0.59–0.89 0.002
Abbreviations: HR¼hazard ratio; CI¼confidence interval; IELSG¼International
Extranodal Lymphoma Study Group; HD-MTX¼high-dose methotrexate;
HD-AraC¼high-dose cytarabine; AUC¼area under the curve; Ref¼reference.
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that tumour response was usually seen within the first two courses
of chemotherapy (Ferreri et al, 2009) does suggest a strong
correlation between first-course PK data and clinical outcome.
In a retrospective study (Ferreri et al, 2004), PCNSL patients
treated with MTX-based chemotherapy and an AUCHD-MTX
41100mmol*l
 1h showed significantly better response and
survival rates. In the IELSG no. 20 trial, only 22% of patients
achieved this AUCHD-MTX, suggesting room for improving
HD-MTX administration. Importantly, a suboptimal AUCHD-MTX
was obtained equally in both treatment arms in the IELSG no.
20 trial. Therefore, the introduction of a personalised dose of
HD-MTX, according to patient age, gender and CLCREA, has the
potential to significantly improve treatment activity in these
patients, and should be investigated in future trials. According to
the present observation, personalisation of the MTX adminis-
tration schedule should not consider the concomitant use of
HD-araC, as the addition of this drug did not change MTX PK.
However, this has to be taken with caution, considering
the potential for increased toxicity with the combined use of
HD-MTX/HD-AraC.
In conclusion, individualised dosing of HD-MTX might have the
potential to improve clinical outcome in patients with PCNSL, even
when administered concurrently with HD-AraC. In the future, this
could be carried out by using first-cycle PK modelling with
determination of potential dose adaptations for later cycles using
Bayesian analysis.
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